Serum levels of fibroblast growth factor‐21 are increased in chronic and acute renal dysfunction. (12th January 2014)
- Record Type:
- Journal Article
- Title:
- Serum levels of fibroblast growth factor‐21 are increased in chronic and acute renal dysfunction. (12th January 2014)
- Main Title:
- Serum levels of fibroblast growth factor‐21 are increased in chronic and acute renal dysfunction
- Authors:
- Hindricks, Janka
Ebert, Thomas
Bachmann, Anette
Kralisch, Susan
Lössner, Ulrike
Kratzsch, Jürgen
Stolzenburg, Jens‐Uwe
Dietel, Anja
Beige, Joachim
Anders, Matthias
Bast, Ingolf
Blüher, Matthias
Stumvoll, Michael
Fasshauer, Mathias - Abstract:
- <abstract abstract-type="main" id="cen12380-abs-0001"> <title>Summary</title> <sec id="cen12380-sec-0001" sec-type="section"> <title>Objective</title> <p>Fibroblast growth factor (FGF)‐21 has recently been introduced as a circulating adipokine which reverses insulin resistance and obesity in rodents. In this study, regulation of FGF‐21 in renal dysfunction was elucidated in both chronic kidney disease (CKD) and acute kidney dysfunction (AKD).</p> </sec> <sec id="cen12380-sec-0002" sec-type="section"> <title>Study design and methods</title> <p>Serum concentrations of total FGF‐21 were quantified by enzyme‐linked immunosorbent assay in 499 patients with CKD stages 1–5 (study population 1). Furthermore, total FGF‐21 was determined before and within 30 h after unilateral nephrectomy, a model of AKD, in 32 patients (study population 2). FGF‐21 levels were correlated to anthropometric and biochemical parameters of renal function, glucose and lipid metabolism, as well as inflammation, in both studies.</p> </sec> <sec id="cen12380-sec-0003" sec-type="section"> <title>Results</title> <p>In study population 1, median [interquartile range] circulating FGF‐21 adjusted for age, gender and body mass index was significantly different between CKD stages with highest values detectable in stage 5 (stage 1: 86·4 [132·9]; 2: 206·4 [223·1]; 3: 289·8 [409·3]; 4: 591·3 [789·0]; 5: 1918·1 [4157·0] ng/l). Furthermore, estimated glomerular filtration rate remained a strong independent and negative<abstract abstract-type="main" id="cen12380-abs-0001"> <title>Summary</title> <sec id="cen12380-sec-0001" sec-type="section"> <title>Objective</title> <p>Fibroblast growth factor (FGF)‐21 has recently been introduced as a circulating adipokine which reverses insulin resistance and obesity in rodents. In this study, regulation of FGF‐21 in renal dysfunction was elucidated in both chronic kidney disease (CKD) and acute kidney dysfunction (AKD).</p> </sec> <sec id="cen12380-sec-0002" sec-type="section"> <title>Study design and methods</title> <p>Serum concentrations of total FGF‐21 were quantified by enzyme‐linked immunosorbent assay in 499 patients with CKD stages 1–5 (study population 1). Furthermore, total FGF‐21 was determined before and within 30 h after unilateral nephrectomy, a model of AKD, in 32 patients (study population 2). FGF‐21 levels were correlated to anthropometric and biochemical parameters of renal function, glucose and lipid metabolism, as well as inflammation, in both studies.</p> </sec> <sec id="cen12380-sec-0003" sec-type="section"> <title>Results</title> <p>In study population 1, median [interquartile range] circulating FGF‐21 adjusted for age, gender and body mass index was significantly different between CKD stages with highest values detectable in stage 5 (stage 1: 86·4 [132·9]; 2: 206·4 [223·1]; 3: 289·8 [409·3]; 4: 591·3 [789·0]; 5: 1918·1 [4157·0] ng/l). Furthermore, estimated glomerular filtration rate remained a strong independent and negative predictor of FGF‐21. In study population 2, FGF‐21 increased significantly postsurgically (325·0 [984·0] ng/l) as compared to presurgical values (255·5 [243·0] ng/l). Furthermore, relative changes of FGF‐21 were independently and positively predicted by relative changes of creatinine.</p> </sec> <sec id="cen12380-sec-0004" sec-type="section"> <title>Conclusions</title> <p>We demonstrate that circulating FGF‐21 is increased in both CKD and AKD. Our results suggest renal excretion as a major route for FGF‐21 elimination. The pathophysiological significance of these findings needs to be elucidated in more detail.</p> </sec> </abstract> … (more)
- Is Part Of:
- Clinical endocrinology. Volume 80:Number 6(2014:Jun.)
- Journal:
- Clinical endocrinology
- Issue:
- Volume 80:Number 6(2014:Jun.)
- Issue Display:
- Volume 80, Issue 6 (2014)
- Year:
- 2014
- Volume:
- 80
- Issue:
- 6
- Issue Sort Value:
- 2014-0080-0006-0000
- Page Start:
- 918
- Page End:
- 924
- Publication Date:
- 2014-01-12
- Subjects:
- Endocrinology -- Periodicals
616.4005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2265 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cen.12380 ↗
- Languages:
- English
- ISSNs:
- 0300-0664
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.278000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 2979.xml